Atossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-MarketGlobeNewsWire • 01/06/21
Atossa Therapeutics Announces Pricing of $14.0 Million Registered Direct Offering Priced At-The-MarketGlobeNewsWire • 12/17/20
Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public OfferingGlobeNewsWire • 12/09/20
Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/13/20
Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19GlobeNewsWire • 11/10/20
New Research Points to the People's Liberation Army Hospital in Wuhan, China as the Origin for the Worldwide Coronavirus PandemicPRNewsWire • 10/28/20
Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVIDGlobeNewsWire • 10/19/20
Registration Is Now Open For Atossa Therapeutics’ Tribe Public Webinar Presentation and Q&A Event On October 13, 2020GlobeNewsWire • 10/07/20
Physician-Scientist Dr. Steven Quay Provides Best-Selling Book, "Stay Safe: A Physician's Guide to Survive Coronavirus," to the White House Upon the News of COVID in the First FamilyPRNewsWire • 10/02/20
Atossa Therapeutics To Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020GlobeNewsWire • 09/21/20
Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVIDGlobeNewsWire • 09/17/20
Atossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical Study of AT-301 Nasal Spray Being Developed for COVID-19GlobeNewsWire • 09/01/20
Atossa Therapeutics to Present at the LD Micro 500 Virtual Conference on September 4, 2020GlobeNewsWire • 08/26/20
Atossa Therapeutics Announces Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray Being Developed for Treatment of COVID-19GlobeNewsWire • 08/17/20
Atossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/13/20
Atossa Therapeutics Receives Approval to Open Clinical Study of AT-301 Nasal Spray Being Developed to Treat COVID-19GlobeNewsWire • 08/03/20
Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with EndoxifenGlobeNewsWire • 07/30/20
Registration Is Now Open for Atossa Therapeutics’ Tribe Public Webinar Presentation and Q&A Event on July 30, 2020GlobeNewsWire • 07/27/20
Atossa Therapeutics Contracts for Clinical Study of AT-301 Nasal Spray, Atossa’s Second COVID-19 Therapeutic Development ProgramGlobeNewsWire • 07/16/20
Atossa Therapeutics Announces Successful In Vitro Testing of Nasal Spray Formulation: AT-301 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory CultureGlobeNewsWire • 07/15/20
Atossa Therapeutics Advances Product Development Programs with Multiple Key Hires in Clinical, Regulatory, and Chemistry Manufacturing and ControlsGlobeNewsWire • 07/08/20
Atossa Therapeutics Announces Availability of Manuscript on Results from In vitro Testing of COVID-19 Drug, AT-H201GlobeNewsWire • 06/11/20
Atossa Therapeutics Announces Second COVID-19 Therapeutic Development Program, AT-301 Nasal Spray: Summit Biosciences Retained to Develop and Supply AT-301 Nasal Spray for Clinical StudyGlobeNewsWire • 05/28/20